title: Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?
abstract: Hematopoietic stem cells from 4 different sources have been or are being used for the reconstitution of lymphohematopoietic function after myeloablative, near-myeloablative, or nonmyeloablative treatment. Bone marrow (BM)-derived stem cells, introduced by E. D. Thomas in 1963, are considered the classical stem cell source. Fetal liver stem cell transplantation has been performed on a limited number of patients with aplastic anemia or acute leukemia, but only transient engraftment has been demonstrated. Peripheral blood as a stem cell source was introduced in 1981, and cord blood was introduced as a source in 1988. The various stem cell sources differ in their reconstitutive and immunogenic characteristics, which are based on the proportion of early pluripotent and self-renewing stem cells to lineage-committed late progenitor cells and on the number and characteristics of accompanying "accessory cells" contained in stem cell allografts.
authors.affiliation: Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston 77030, USA. mkorblin@mdanderson.org
authors.forename: M
authors.initials: M
authors.lastname: Körbling
authors.forename: P
authors.initials: P
authors.lastname: Anderlini
mesh_terms: D001773:Blood Cells / Q000637:transplantation; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000401:mortality; D002908:Chronic Disease; D005312:Fetal Blood / Q000166:cytology; D000069585:Filgrastim; D005500:Follow-Up Studies; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000209:etiology; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000494:pharmacology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D006412:Hematopoietic Stem Cells; D006801:Humans; D016130:Immunophenotyping; D007937:Leukapheresis; D007958:Leukocyte Count; D008099:Liver / Q000166:cytology / Q000196:embryology; D008213:Lymphocyte Activation; D009000:Monocytes / Q000187:drug effects / Q000502:physiology; D015337:Multicenter Studies as Topic; D009504:Neutrophils / Q000166:cytology; D009928:Organ Specificity; D010976:Platelet Count; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000494:pharmacology; D012042:Registries; D012189:Retrospective Studies; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014019:Tissue Donors; D009927:Tissue and Organ Procurement / Q000379:methods; D014184:Transplantation, Homologous
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000069585:Filgrastim